Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Iovate intros new Hydroxycut formula

This article was originally published in The Tan Sheet

Executive Summary

Iovate Health Sciences introduces a new formula for its Hydroxycut line, Thermogenic Hydroxycut Advanced. The product's Web site advertises the formula as containing "all-natural antioxidants," and says the product's key ingredient, caffeine anhydrous, helps increase energy and boost metabolism. The firm withdrew 14 products from its Hydroxycut line May 1 after FDA investigated 23 reports of serious liver-related adverse events - including one death - dating to 2002 (1"The Tan Sheet" May 18, 2009). FDA confirmed that "the only ingredient left in from the original formulation is caffeine" and said it "does not have any evidence that caffeine causes liver toxicity." The firm declined to comment

You may also be interested in...

Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs

The dietary supplement industry looks to FDA's Hydroxycut investigation for a sign on whether the agency will analyze adverse event reports more closely following a high-profile product recall

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts